FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384126750> ?p ?o ?g. }

• W4384126750 endingPage "3874" @default.
• W4384126750 startingPage "3867" @default.
• W4384126750 abstract "Early treatment intensification with neoadjuvant therapy may improve outcomes in patients with high-risk, localized prostate cancer treated with radical prostatectomy. Our objective was to compare pathologic, oncologic, and safety outcomes of neoadjuvant abiraterone acetate plus leuprolide acetate with or without cabazitaxel prior to radical prostatectomy in patients with localized, high-risk prostate cancer.This open-label, multicenter, phase II trial randomized men with clinically localized, D'Amico high-risk prostate cancer to neoadjuvant abiraterone acetate (1,000 mg/day) and leuprolide acetate (22.5 mg every 3 months) with or without cabazitaxel (25 mg/m2) prior to radical prostatectomy. The primary outcome was pathologic complete response (pCR) or minimal residual disease (MRD). Secondary outcomes included surgical margins, lymph node involvement, pathologic stage, 12-month biochemical relapse-free survival (BRFS) rates, and safety profile.The per-protocol population consisted of 70 patients [cabazitaxel arm (Arm A): 37, no cabazitaxel arm (Arm B): 33]. Median patient age and prostate-specific antigen levels were 63.5 years [interquartile range (IQR), 58.0-68.0] and 21.9 ng/mL (IQR, 14.6-42.8), respectively. pCR/MRD occurred in 16 (43.2%) versus 15 patients (45.5%) in arms A and B, respectively (P = 0.85). pCR occurred in two (5.4%) versus three patients (9.1%) in arms A and B, respectively (P = 0.66). Patients with ≤ 25% total biopsy cores positive had increased odds of pCR/MRD (P = 0.04). Patients with pCR/MRD had superior 12-month BRFS rates (96.0% vs. 62.0%, P = 0.03). Grade 3+ adverse events occurred in 42.5% and 23.7% of patients in arms A and B, respectively (P = 0.078).Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to radical prostatectomy did not improve pCR/MRD in clinically localized, high-risk prostate cancer." @default.
• W4384126750 created "2023-07-14" @default.
• W4384126750 creator A5001885553 @default.
• W4384126750 creator A5002629653 @default.
• W4384126750 creator A5007710281 @default.
• W4384126750 creator A5012397578 @default.
• W4384126750 creator A5016589383 @default.
• W4384126750 creator A5018908850 @default.
• W4384126750 creator A5024327224 @default.
• W4384126750 creator A5037656416 @default.
• W4384126750 creator A5042123586 @default.
• W4384126750 creator A5046679576 @default.
• W4384126750 creator A5048218891 @default.
• W4384126750 creator A5055091318 @default.
• W4384126750 creator A5057500759 @default.
• W4384126750 creator A5062740324 @default.
• W4384126750 creator A5073406780 @default.
• W4384126750 creator A5074359131 @default.
• W4384126750 creator A5078745076 @default.
• W4384126750 creator A5081688624 @default.
• W4384126750 creator A5085333470 @default.
• W4384126750 creator A5086078883 @default.
• W4384126750 creator A5088388062 @default.
• W4384126750 date "2023-07-13" @default.
• W4384126750 modified "2023-10-18" @default.
• W4384126750 title "Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial" @default.
• W4384126750 cites W1717462707 @default.
• W4384126750 cites W2003937196 @default.
• W4384126750 cites W2020031575 @default.
• W4384126750 cites W2104530249 @default.
• W4384126750 cites W2117792530 @default.
• W4384126750 cites W2132047057 @default.
• W4384126750 cites W2137996608 @default.
• W4384126750 cites W2148143162 @default.
• W4384126750 cites W2167749314 @default.
• W4384126750 cites W2264105361 @default.
• W4384126750 cites W2553214654 @default.
• W4384126750 cites W2901886450 @default.
• W4384126750 cites W2916580364 @default.
• W4384126750 cites W2948197666 @default.
• W4384126750 cites W3045271368 @default.
• W4384126750 cites W3092285337 @default.
• W4384126750 cites W3102901386 @default.
• W4384126750 cites W3134592109 @default.
• W4384126750 cites W3137537012 @default.
• W4384126750 cites W3200856992 @default.
• W4384126750 cites W4223443163 @default.
• W4384126750 cites W4233044725 @default.
• W4384126750 cites W4296929270 @default.
• W4384126750 doi "https://doi.org/10.1158/1078-0432.ccr-23-0731" @default.
• W4384126750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37439809" @default.
• W4384126750 hasPublicationYear "2023" @default.
• W4384126750 type Work @default.
• W4384126750 citedByCount "0" @default.
• W4384126750 crossrefType "journal-article" @default.
• W4384126750 hasAuthorship W4384126750A5001885553 @default.
• W4384126750 hasAuthorship W4384126750A5002629653 @default.
• W4384126750 hasAuthorship W4384126750A5007710281 @default.
• W4384126750 hasAuthorship W4384126750A5012397578 @default.
• W4384126750 hasAuthorship W4384126750A5016589383 @default.
• W4384126750 hasAuthorship W4384126750A5018908850 @default.
• W4384126750 hasAuthorship W4384126750A5024327224 @default.
• W4384126750 hasAuthorship W4384126750A5037656416 @default.
• W4384126750 hasAuthorship W4384126750A5042123586 @default.
• W4384126750 hasAuthorship W4384126750A5046679576 @default.
• W4384126750 hasAuthorship W4384126750A5048218891 @default.
• W4384126750 hasAuthorship W4384126750A5055091318 @default.
• W4384126750 hasAuthorship W4384126750A5057500759 @default.
• W4384126750 hasAuthorship W4384126750A5062740324 @default.
• W4384126750 hasAuthorship W4384126750A5073406780 @default.
• W4384126750 hasAuthorship W4384126750A5074359131 @default.
• W4384126750 hasAuthorship W4384126750A5078745076 @default.
• W4384126750 hasAuthorship W4384126750A5081688624 @default.
• W4384126750 hasAuthorship W4384126750A5085333470 @default.
• W4384126750 hasAuthorship W4384126750A5086078883 @default.
• W4384126750 hasAuthorship W4384126750A5088388062 @default.
• W4384126750 hasConcept C119060515 @default.
• W4384126750 hasConcept C121608353 @default.
• W4384126750 hasConcept C126322002 @default.
• W4384126750 hasConcept C126894567 @default.
• W4384126750 hasConcept C143998085 @default.
• W4384126750 hasConcept C2775832370 @default.
• W4384126750 hasConcept C2777511904 @default.
• W4384126750 hasConcept C2777899217 @default.
• W4384126750 hasConcept C2778292576 @default.
• W4384126750 hasConcept C2778971682 @default.
• W4384126750 hasConcept C2779466945 @default.
• W4384126750 hasConcept C2780192828 @default.
• W4384126750 hasConcept C530470458 @default.
• W4384126750 hasConcept C71924100 @default.
• W4384126750 hasConceptScore W4384126750C119060515 @default.
• W4384126750 hasConceptScore W4384126750C121608353 @default.
• W4384126750 hasConceptScore W4384126750C126322002 @default.
• W4384126750 hasConceptScore W4384126750C126894567 @default.
• W4384126750 hasConceptScore W4384126750C143998085 @default.
• W4384126750 hasConceptScore W4384126750C2775832370 @default.
• W4384126750 hasConceptScore W4384126750C2777511904 @default.
• W4384126750 hasConceptScore W4384126750C2777899217 @default.

• next